{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260622057174/en/Merck%E2%80%99s-Tulisokibart-Met-Primary-and-Key-Secondary-Endpoints-in-the-Phase-3-ATLAS-UC-Induction-only-Study-in-Patients-With-Moderately-to-Severely-Active-Ulcerative-Colitis-UC", "message": "News view counter 808906 successfully enlarged"}